The emerging science of precision psychiatry – which aims to understand and directly treat the biology behind psychotic disorders such as schizophrenia – lies at the core of Boehringer Ingelheim GmbH’s central nervous system research and development program. Its freshly signed collaboration with the US-based Lieber Institute for Brain Development should advance those efforts, BI’s recently-appointed head of CNS disease R&D Hugh Marston told Scrip.
Boehringer Ingelheim To Focus On Precision Psychiatry In CNS
R&D Mission: Explore Brain’s Biological Circuitry
Boehringer Ingelheim will increasingly use external collaborations in its search for new treatment options for neuropsychiatric diseases, its CNS R&D head tells Scrip.
More from Business
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from Scrip
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.